Silence Therapeutics Plc SLN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$19.73 up $0.01, 0.05% at close Nov 6
Last close · Previous close $19.72
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.32Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$19.73up $0.01, 0.05%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$19.72Nov 5
- Volume958.19KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume5.61MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $4.19 to $19.87; now $19.73
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SLN beat the S&P 500 in 5 of 6 periods.
| Period | SLN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SLN: up 100.7% S&P 500: down 5.6% | SLN beat the S&P 500 by 106.3 percentage points Beat |
| 3M | SLN: up 68.3% S&P 500: down 4.1% | SLN beat the S&P 500 by 72.4 percentage points Beat |
| YTD | SLN: up 224.5% S&P 500: up 8.7% | SLN beat the S&P 500 by 215.8 percentage points Beat |
| 1Y | SLN: up 205.9% S&P 500: up 10.9% | SLN beat the S&P 500 by 195.0 percentage points Beat |
| Long term | ||
| 3Y | SLN: up 95.5% S&P 500: up 75.0% +25.0% vs +20.5% a year | SLN beat the S&P 500 by 20.5 percentage points Beat |
| 5Y | SLN: down 13.8% S&P 500: up 67.8% −2.9% vs +10.9% a year | SLN trailed the S&P 500 by 81.6 percentage points Trailed |
$10,000 invested in SLN 5 years ago (Nov 5, 2021) would be worth about $8,623 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
SLN beat the S&P 500 in 5 of 6 periods.
| Period | SLN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SLN: up 100.7% S&P 500: down 5.6% | SLN beat the S&P 500 by 106.3 percentage points Beat |
| 3M | SLN: up 68.3% S&P 500: down 4.3% | SLN beat the S&P 500 by 72.6 percentage points Beat |
| YTD | SLN: up 224.5% S&P 500: up 7.8% | SLN beat the S&P 500 by 216.7 percentage points Beat |
| 1Y | SLN: up 205.9% S&P 500: up 9.7% | SLN beat the S&P 500 by 196.2 percentage points Beat |
| Long term | ||
| 3Y | SLN: up 95.5% S&P 500: up 68.8% +25.0% vs +19.1% a year | SLN beat the S&P 500 by 26.7 percentage points Beat |
| 5Y | SLN: down 13.8% S&P 500: up 56.9% −2.9% vs +9.4% a year | SLN trailed the S&P 500 by 70.7 percentage points Trailed |
$10,000 invested in SLN 5 years ago (Nov 5, 2021) would be worth about $8,623 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$28.35
Closing high on . Now 30.4% below that record.
Split-adjusted daily closes since Sep 8, 2020.
Stock splits
SLN hasn’t split since its price history begins in 2020.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $615.00Kdown 97.7%
- Net income
- −$59.95M
- Diluted EPS
- −$1.32
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $1.50M | −$35.54M | −$0.75 |
| Q4 FY24 (Dec 31, 2024) | $25.31M | $12.30M | $0.27 |
| Q1 FY25 (Mar 31, 2025) | $142.00K | −$28.53M | −$0.60 |
| Q2 FY25 (Jun 30, 2025) | $224.00K | −$27.35M | −$0.57 |
| Q3 FY25 (Sep 30, 2025) | $159.00K | −$20.96M | −$0.45 |
| Q4 FY25 (Dec 31, 2025) | $34.00K | −$11.77M | −$0.27 |
| Q1 FY26 (Mar 31, 2026) | $422.00K | −$14.96M | −$0.33 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$12.27M | −$0.27 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $15.52M | −$49.26M | Not reported |
| FY22 (Dec 31, 2022) | $21.66M | −$50.33M | −$1.56 |
| FY23 (Dec 31, 2023) | $31.64M | −$54.23M | −$1.47 |
| FY24 (Dec 31, 2024) | $43.26M | −$45.31M | −$0.99 |
| FY25 (Dec 31, 2025) | $559.00K | −$88.61M | −$1.89 |
Margins
- Gross 85.9%
- Operating −11,106.8%
- Net −9,748.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$42.27MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$42.26MLast 12 months
- Capital spending$3.00KLast 12 months
- −6,872.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $2.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $72.05MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$112.00KAs of Jun 30, 2026
- Net cash$71.94MAs of Jun 30, 2026
- 7.42As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −48.0%Last 12 months
Over the last 12 months, Silence Therapeutics’s net loss was 48.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Silence Therapeutics Plc
Silence Therapeutics Plc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- United Kingdom
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
SLN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SLN stock FAQ
What is SLN stock’s price today?
Silence Therapeutics (SLN) traded at $19.73 at the close on , up $0.01 (0.05%) from the previous close of $19.72. Over the past 52 weeks it has traded between $4.19 and $19.87.
If you invested $1,000 in SLN 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in SLN on would be worth about $862 at the close on , a total return of −13.8%. The same $1,000 would be worth $3,059 if invested one year ago. Past performance doesn’t predict future returns.
What is SLN’s P/E ratio?
SLN’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.32).
How much revenue does Silence Therapeutics make?
Silence Therapeutics reported $615.0 thousand of revenue over the four quarters to , down 97.7% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $0.0 thousand, down 100.0% from a year earlier.
Is Silence Therapeutics profitable?
Not over the four quarters to . Silence Therapeutics reported a net loss of $60.0 million across those four quarters on $615.0 thousand of revenue.
What are SLN’s earnings per share?
SLN’s diluted earnings per share were −$1.32 over the four quarters to , compared with −$1.65 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.27 per share, against −$0.57 a year earlier (how EPS works).
Does SLN pay a dividend?
Silence Therapeutics hasn’t paid a dividend in the last twelve months.
What is SLN’s 52-week high and low?
Over the past 52 weeks SLN has traded as low as $4.19 and as high as $19.87. At $19.73 at the close on , it is 0.7% below that high and 370.9% above the low.
What is SLN’s all-time high?
SLN’s highest closing price was $28.35 on , adjusted for stock splits. At $19.73 at the close on , it is 30.4% below that record.
Has SLN stock ever split?
No. SLN hasn’t split since its price history begins in 2020.
How has SLN stock performed?
Including dividends and measured to the close on , SLN has returned +224.5% so far this year and +205.9% over the past year, and −13.8% over five years (−2.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Silence Therapeutics in?
Silence Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in United Kingdom.
What exchange does SLN trade on?
Silence Therapeutics trades on the Nasdaq under the ticker symbol SLN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.